Skip to main content
Psyence Group Inc. logo

Psyence Group Inc. — Investor Relations & Filings

Ticker · PSYG ISIN · CA74449Q2053 LEI · 549300RPEOIVSD0MJC07 CSE Manufacturing
Open in API
Filings indexed 195 across all filing types
Latest filing 2023-01-24 Regulatory Filings
Country CA Canada
Listing CSE PSYG

About Psyence Group Inc.

https://psyence.com/

Psyence Group Inc. is a science-led life science biotechnology company focused on the research, cultivation, and production of natural psychedelics and nature-based compounds. The company develops innovative, safe, and effective solutions for mental health. Its core clinical division, Psyence Therapeutics (now part of Psyence Biomedical Ltd.), pioneers the use of natural psilocybin formulations and treatment protocols, primarily targeting anxiety and depression within the context of palliative care. Supporting this effort, the company operates one of the world's first federally licensed, ISO22000 certified psilocybin cultivation and production facilities. Furthermore, Psyence Function markets a range of non-psychoactive functional mushroom wellness products utilizing adaptogens.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new partnership and collaboration between Psyence Group Inc. and Eden Labs LLC. It details the nature of the collaboration, the appointment of a new advisory board member, and the issuance of shares as part of the partnership. There is no financial data, regulatory filing references, or detailed financial reports included. The content focuses on business development and strategic partnership announcements rather than financial results, governance changes, or regulatory filings. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate update that does not fit other specific categories.
2023-01-24 English
Notice of the meeting and record date - English.pdf
AGM Information Classification · 90% confidence The document is a notice regarding the upcoming Annual General Meeting (AGM) of Psyence Group Inc., specifying the meeting date, record date, and other procedural details. It does not contain the AGM materials or presentations themselves, nor does it include financial data or voting results. The document is short (1088 characters) and serves as an announcement of the meeting and record date. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or AGM Information (AGM-R). However, since it is a notice of meeting and record date rather than voting results or AGM materials, it aligns most closely with AGM Information (AGM-R) which covers presentations and materials shared during the AGM process, including notices related to the AGM. Confidence is high due to clear meeting details and the nature of the document as a meeting notice.
2023-01-23 English
Material change report - English.pdf
M&A Activity Classification · 95% confidence The document is a Form 51-102F3 Material Change Report filed by Psyence Group Inc. It announces a definitive business combination agreement with Newcourt Acquisition Corp, a SPAC, to create a public company. The document includes detailed descriptions of the transaction, key terms, closing conditions, and references to filings with the SEC such as Form 8-K and Form F-4. The content focuses on a merger/business combination announcement rather than financial results, governance, or other report types. This fits the definition of M&A Activity (TAR) filings, which cover announcements and documents related to merger proposals or takeover bids. The document is substantive and not merely an announcement of a report, so it is not RPA or RNS. Therefore, the correct classification is TAR with high confidence.
2023-01-09 English
News release - English.pdf
M&A Activity Classification · 95% confidence The document is a detailed announcement of a business combination agreement between Psyence Biomed Corp and Newcourt Acquisition Corp, describing the terms, conditions, and expected outcomes of the merger. It includes information about the transaction structure, financing, regulatory filings to be made (Form 8-K, Form F-4), and proxy statements to be filed with the SEC. The content focuses on the merger proposal and related corporate actions rather than financial results, management changes, or regulatory compliance filings. This fits the definition of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids. The document is lengthy (15,000 characters) and contains substantive details about the transaction, not just an announcement of a report or a brief summary. Therefore, the appropriate classification is TAR with high confidence.
2023-01-09 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Psyence Group Inc has signed a Letter of Intent (LOI) with a Contract Research Organization (CRO) to conduct clinical trials for a psilocybin drug candidate. It discusses the clinical development strategy, trial design, and regulatory environment but does not contain any financial data, financial results, or detailed report content. It is an announcement of a business development event rather than a financial or regulatory filing. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other formal financial or regulatory filing. The document is a corporate announcement about a strategic partnership and clinical trial plans, which fits best under the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2023-01-09 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a worldwide licensing agreement between Psyence Group Inc and Filament Health Corp regarding a psilocybin drug candidate for palliative care. It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed financial or operational reports. The content is primarily a corporate announcement about a commercial licensing agreement and partnership expansion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any detailed financial or governance report. It is a typical corporate news announcement about a business development. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and miscellaneous filings that do not fit other categories.
2022-12-15 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.